We're closing in fast on 600,000 downloads of the Business of Biotech podcast, and while that "vanity metric" is fun to watch, it's not what I get most excited about. What gets me excited and puts fuel to the Business of Biotech engine is the interaction with listeners, the feedback, the constructive criticism, the guest suggestions, the picks and the pans. Numbers are cool, but they don't capture impact and feed improvement like interactions do.
There are several ways to join the conversation. The most direct is matt.pillar@lifescienceconnect.com, where you can praise or skewer direct to my inbox. LinkedIn, where I'm at linkedin.com/in/matthewpillar, is great too. If you listen on a podcast platform, there's a fan mail link in the episode notes that comes straight to my inbox (also let me know if you're not a fan).
What do you want to hear about? Who do you want to hear it from? Let me know and I'll get on it!
This month's Business of Biotech newsletter features some favorited columns from the Life Science Connect community with insight on clinical trial investigations, PBMs and healthcare spending models, a first-of-its-kind cell therapy that's soon to hit the clinic, and the risks of AI in drug discovery and development. For more on that, tune in to the next Bioprocess Online Live, Sept. 4 at 11 AM ET, for an interactive conversation on where AI is actually happening, beyond discovery, with our own Tyler Menichiello and an expert panel.
In the meantime, enjoy the newsletter and get in touch! Matt Pillar, Business of Biotech host and chief editor, Bioprocess Online |
|
| | Biotech Beat | August 20, 2024 |
|
| ![]() | | Stories like those told on episode 210 make us a bit bullish on AI in biologics discovery and development. But every now and then, we need to take a beat and consider the risks AI brings to the table. This reality check was brought to you by Bioprocess Online contributors Remco Jan Geukes Foppen and Vincenzo Gioia, who offer some great advice on verification procedures to ensure your AI outcomes aren't trippin'. | READ NOW → |
|
![]() | | by BEN COMER | On episode 201 of the Business of Biotech, our buddy Allan Shaw went long on his disdain for PBMs. Patient demand for GLP-1 drugs has forced a new model, as covered in this Life Science Leader piece featuring PwC's Philip Sclafani and Ben Comer. The pair also explore the medical cost inflation trends, and interestingly, the IRA isn't one of them. Yet. | READ NOW → |
|
| ![]() | | by ERIN HARRIS | If you've been with us for a while, you'll remember that Umoja Biopharma COO David Fontana, Ph.D. joined us about 100 episodes back to share progress on an in-vivo CAR T-cell therapy candidate. Well, it's about to enter the clinic—and that's a first—so Cell & Gene's Erin Harris caught up with Fontana to learn what it took to get there. | READ NOW → |
|
![]() | | by DAN SCHELL | Vincent Cafiso saw his fair share of red flags while investigating clinical trial sites for the FDA. Often, those red flags came in the form of the words emitting from a nervous and oversharing clinician's mouth. Cafiso puts what not to ask, or say, in real terms in this fun and enlightening read from Clinical Leader's Dan Schell. | READ NOW → |
|
| | "The professor had an engineering degree and a doctorate in business administration. I asked him, how did you adjust to this? He said, Enrique, in business, 80% is good enough." | ― Enrique Diloné, Ph.D., Chief Technology Officer, Immunity Bio, Episode 211 |
|
| "The worst case scenario is you spend four or five years making a platform that's really only enabled to make one asset. That's not exactly the best use of capital." | ― John Lepore, M.D., CEO, ProFound Therapeutics, Episode 212 |
|
| "In a small company, the people are the people. You had better like them. You're going to spend a lot of time with them, so make your choice very carefully." | ― Kristin Yarema, Ph.D., CEO, Poseida Therapeutics, Episode 213 |
|
| | | ![]() | Created exclusively for the leaders of new and emerging biopharma firms, the Business of Biotech podcast tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success. Check out our episode archive. | |
|
|
|
Ensure our newsletter reaches your inbox by following these whitelist instructions.
This newsletter is being sent to {{lead.Email Address}}. To cancel your subscription to the newsletter, please opt out. | © Copyright 2024 Vertmarkets, Inc. 5340 Fryling Rd Suite 100, Erie, PA 16510.
All rights reserved. All product names contained herein are the trademarks of their respective holders. |
|
|
|
|
